Euglycemic Diabetic Ketoacidosis in COVID-19 Patient Caused by Empagliflozin: A Case Report from Intensive Care Unit
Abstract
The novel coronavirus - Severe Acute Respiratory Syndrome coronavirus 2 - is responsible for mainly respiratory disease (COVID-19). On the other hand, Diabetic Ketoacidosis (DKA) is a life-threating complication. The usual form of DKA is caused by insulin deficiency and is characterized by high blood glucose (usually more than 250mg/dl or 14mmol/L), ketonemia, low pH, and low serum bicarbonate. The other form of DKA is the euglycemic DKA, which occurs in patients with blood glucose lower than 250mg/dl (14mmol/L). This case report describes a patient that presented to the intensive care unit with Covid-19 pneumonia and euglycemic DKA.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.